In addition to the underlying mechanism of cardiac protection, substantial evidence has suggested that SGLT2 inhibitors also help to reverse the molecular processes related to inflammation, extracellular matrix turnover, and fibrosis in patients with diabetic nephropathy, with long-term protection of renal function (Gallo et al., 2016; Aroor et al., 2018; Zhang et al., 2018; Heerspink et al., 2019). This evidence concerns the gene SLC5A2 and diabetic kidney disease.